drugset / Trial / NCT04600999

Clinical Trial of Favipiravir Treatment of Patients With COVID-19

NCT04600999

RandomizedParallel-groupOpen-labelTreatment

Summary

To verify that the efficacy of favipiravir exceeds that of the actual supportive care (symptomatic therapy) in SARS-CoV-2 infected patients (COVID-19 patients) with mild pneumonia, using the time required to improve clinical symptoms as the primary endpoint.

Timeline

Start
2020-10-07
Primary completion
2020-12-28
Completion
2020-12-28

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Favipiravir Small molecule 800 mg Oral

Indications